Lumen Bio is a clinical-stage biotech company with a drug development and manufacturing platform that offers potential to transform the biologics industry. Their platform allows for increased speed, mass-market scale, and lower costs than current approaches. They focus on developing topically and mucosally delivered biologic drugs to treat and prevent highly prevalent diseases that currently lack effective treatments. Their clinical pipeline includes investigational biologic drugs for C. difficile infection, Covid-19, norovirus, traveler's diarrhea, and inflammatory bowel disease. Additionally, they develop oral antibody therapeutics to provide clinicians with therapeutics against disease targets that were previously inaccessible to the biopharmaceutical industry.